Q32 Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	53.74	-	-6.65	3.21	33.97
Revenue Growth (YoY)	-	-	-	-90.56%	1157.25%
Gross Profit	53.74	-	-6.65	3.21	33.97
Selling, General & Admin	17.68	17.96	9.88	38.14	36.84
Research & Development	19.16	48.14	31.73	98.35	93.09
Total Operating Expenses	36.84	66.1	41.6	136.49	129.92
Operating Income	16.9	-66.1	-48.26	-133.28	-95.95
Other Non-Operating Income (Expense)	11.74	-	-	-	-
Total Non-Operating Income (Expense)	12.92	20.02	-5.17	134.48	0.19
Pretax Income	29.82	-46.09	-53.43	1.2	-95.76
Provision for Income Taxes	-	0.02	0.32	0.72	-
Net Income	29.82	-47.73	-53.74	-5.01	-95.76
Net Income to Common	29.82	-47.73	-53.74	-5.01	-95.76
Shares Outstanding (Basic)	12	9	3	3	3
Shares Outstanding (Diluted)	12	10	3	3	3
Shares Change (YoY)	27.51%	214.45%	-	-	20.41%
EPS (Basic)	2.42	-5.12	-153.96	-6.09	-31.14
EPS (Diluted)	2.42	-6.58	-153.96	-6.09	-31.14
Shares Outstanding	12.86	12.2	0.35	3.19	3.18
Free Cash Flow	-33.54	-67.79	-18.68	-114.95	-112.15
Free Cash Flow Per Share	-2.72	-7.02	-6.08	-37.43	-36.51
Gross Margin	100.00%	-	100.00%	100.00%	100.00%
Operating Margin	31.45%	-	725.53%	-4154.64%	-282.44%
Profit Margin	55.49%	-	808.04%	15.06%	-281.90%
FCF Margin	-62.42%	-	280.89%	-3583.10%	-330.13%
EBITDA	17.29	-65.62	-47.76	-131.99	-87.6
EBITDA Margin	32.18%	-	718.03%	-4114.34%	-257.86%
EBIT	16.9	-66.1	-48.26	-133.28	-95.95
EBIT Margin	31.45%	-	725.53%	-4154.64%	-282.44%
Effective Tax Rate	0.00%	-0.05%	-0.60%	59.68%	0.00%

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q